Read full paper at: http://www.scirp.org/journal/PaperInformation.aspx?PaperID=53324#.VL3BYCzQrzE Author(s) Rania Mohamed 1 , Horace Massa 2 , Claude Schwarz 2 , Nicole Grandjean-Hallez 3 , Kaveh Samii 1 Affiliation(s) 1 Hematology Department, University of Geneva Hospitals, Geneva, Switzerland . 2 Ophtalmology Department, University of Geneva Hospitals, Geneva, Switzerland . 3 Oncology Department, University of Geneva Hospitals, Geneva, Switzerland . ABSTRACT Bortezomib is a novel agent for the treatment of patients with multiple myeloma. Several cutaneous lesions have been associated with its use and chalazia have been reported in a few cases with a delayed appearance ranging from 1 to 6 months. We describe the case of a 59-year-old man with multiple myeloma IgG kappa, ISS2, who developed a chalazion induced by bortezomib. Following the failure of conservative treatment, a biopsy was performed to exclude extramedullary...
Scientific Research Publishing